Hepatitis B News and Research

Latest Hepatitis B News and Research

Pharmaceuticals to provide safe needle collection and disposal programs for patients

It is illegal in the state of California to unsafely dispose of "sharps" (medical waste such as needles and syringes) in the home, and thanks to California State Senator Joe Simitian's Senate Bill 486, and contributors from his annual "There Oughta Be A Law" contest, 1 million Californians will not be breaking the law anymore (see http://www.ciwmb.ca.gov/hhw/sharps/).

13 Oct 2009

Hepatitis A to be included in Expanded Programme on Immunization in 2010

HTDS www.htdsmedical.com (HTDS) - The issuer's China based operating subsidiary Mellow Hope www.mellowhope.com is pleased to announce the clinical protocol is in the process of being approved. It is known that the Hepatitis A will be included in the Expanded Programme on Immunization (EPI) in 2010.

9 Oct 2009

New York Governor participates in roundtable discussion on stem cell research

Albert Einstein College of Medicine of Yeshiva University hosted a roundtable discussion on stem cell research with New York Governor David A. Paterson today. Allen M. Spiegel, M.D., the Marilyn and Stanley M. Katz Dean of Einstein, and eight stem cell researchers discussed advances in medical therapies and treatments that Einstein scientists have been investigating since receiving more than $14 million in State funding for stem cell research.

9 Oct 2009

Digestive Health Outcomes Registry for patients with GI disease

The American Gastroenterological Association (AGA), the leading association representing clinicians and researchers who specialize in the digestive tract, and MedAssurant, Inc., a leading provider of data-driven healthcare solutions, announced today the collaborative initiative to develop a set of registries to assist physicians, payors, policy makers, and other healthcare stakeholders in the study and improvement of clinical and quality outcomes, care management, and cost effectiveness of care delivered to Americans with gastrointestinal disease.

9 Oct 2009

New research report outlines growth prospects of Biomagnetics Diagnostics

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, today announced the Company is the subject of a new research report issued by Emerging Growth Research, LLP.

8 Oct 2009

Antidotes effective for treating acute liver failure patients in early stages of disease

The antidote for acute liver failure caused by acetaminophen poisoning also can treat acute liver failure due to most other causes if given before severe injury occurs, UT Southwestern Medical Center researchers and their colleagues at 21 other institutions have found.

8 Oct 2009

HTDS' Hepatitis A vaccine receives GMP Certificate from the Russian FDA

HTDS www.htdsmedical.com (HTDS) - The issuer's China based operating subsidiary Mellow Hope www.mellowhope.com is pleased to announce that its Hepatitis A Live Attenuated Vaccine (Brand name: Mevac-A) associate operation plant has obtained the GMP Certificate (Good Manufacturing Practice See Description http://en.wikipedia.org/wiki/Good_manufacturing_practice) from the Russian FDA. http://www.who.int/hiv/HIVCP_RUS.pdf

8 Oct 2009

Needlestick injuries in home care nursing can also affect patients

Patients continue to enter home healthcare ''sicker and quicker," often with complex health problems that may require extensive nursing care. This increases the risk of needlestick injuries in home healthcare nurses.

8 Oct 2009

Biostar Pharmaceuticals' new drug application granted clearance for clinical trials

Biostar Pharmaceuticals, Inc. ("Biostar" or "the Company"), a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and medical nutrients addressing a variety of diseases and conditions, today announced that the Chinese Military Drug Administration has granted clearance to begin clinical trials on the Company's new drug application, the Zushima Analgesic Aerosol Spray.

7 Oct 2009

Idera Pharmaceuticals commences phase 1 IMO-2125 clinical trial for chronic HCV infection

Idera Pharmaceuticals, Inc. today announced that patient treatment has been initiated in a phase 1 clinical trial evaluating IMO-2125 in combination with ribavirin in treatment-naive patients with chronic hepatitis C virus (HCV) infection. IMO-2125 is a novel agonist of Toll-like Receptor (TLR) 9.

7 Oct 2009

GlobeImmune to present an abstract of GI-5005 drug at AASLD's annual meeting

GlobeImmune Inc. today announced that a late breaking abstract related to GI-5005, its investigational hepatitis C virus (HCV) product candidate, has been accepted for presentation at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place Oct. 31 through Nov. 4, 2009, in Boston, Mass.

7 Oct 2009

PSI-879 nominated as second development candidate for treating HCV infection

Pharmasset, Inc. announced today the nomination of PSI-352879 (PSI-879) as a second development candidate from two series of purine analogs for the treatment of chronic hepatitis C virus (HCV) infection.

7 Oct 2009

PDS Biotechnology's Versamune-based immunotherapy drug demonstrates safety in preclinical studies

PDS Biotechnology Corporation today announced that the company has completed GLP toxicology studies of its lead HPV-cancer product. The studies, which included pharmacokinetic (PK) and adsorption, bio-distribution and excretion (ADE) studies in addition to the evaluation of toxicity, all demonstrated a very safe profile of the drug and PDS Biotech's platform Versamune((TM)) technology.

6 Oct 2009

Hepatitis B Foundation calls for consistent monitoring and referral of HBV infected children

An expert panel of nationally recognized pediatric liver specialists convened by the Hepatitis B Foundation is calling for more consistent monitoring and referral of children chronically infected with the hepatitis B virus (HBV). The panel's recommendations for pediatricians and other primary care practitioners stress the need for routine monitoring of children with chronic HBV infections, and timely consultation with a pediatric liver specialist.

6 Oct 2009

FDA Advisory Committee approves Peginterferon alfa-2b for treating metastatic melanoma

Enzon Pharmaceuticals, Inc. today announced that the FDA Oncologic Drug Advisory Committee voted in favor of recommending approval of PEGINTRON® as a treatment in addition to surgery in patients with metastatic melanoma.

6 Oct 2009

New study to boost immune cells for pathogen resistance and vaccine efficacy in elderly

A new study from the Trudeau Institute in Saranac Lake, New York, demonstrates that immune system cells important for both pathogen resistance and vaccine efficacy live longer in older animals but because of this longevity acquire functional defects. The work may provide new targets for boosting immune system function in older individuals.

6 Oct 2009

Preclinical study results of AVL-181 protease inhibitor presented

Avila Therapeutics, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, pan-genotype, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181.

5 Oct 2009

Hepatitis B News and Research

Latest Hepatitis B News and Research

Pharmaceuticals to provide safe needle collection and disposal programs for patients

Hepatitis A to be included in Expanded Programme on Immunization in 2010

New York Governor participates in roundtable discussion on stem cell research

Digestive Health Outcomes Registry for patients with GI disease

New research report outlines growth prospects of Biomagnetics Diagnostics

Antidotes effective for treating acute liver failure patients in early stages of disease

HTDS' Hepatitis A vaccine receives GMP Certificate from the Russian FDA

Needlestick injuries in home care nursing can also affect patients

Biostar Pharmaceuticals' new drug application granted clearance for clinical trials

Idera Pharmaceuticals commences phase 1 IMO-2125 clinical trial for chronic HCV infection

GlobeImmune to present an abstract of GI-5005 drug at AASLD's annual meeting

PSI-879 nominated as second development candidate for treating HCV infection

PDS Biotechnology's Versamune-based immunotherapy drug demonstrates safety in preclinical studies

Hepatitis B Foundation calls for consistent monitoring and referral of HBV infected children

FDA Advisory Committee approves Peginterferon alfa-2b for treating metastatic melanoma

New study to boost immune cells for pathogen resistance and vaccine efficacy in elderly

Preclinical study results of AVL-181 protease inhibitor presented

Former President Clinton awards certification for new clean water system

Bristol-Myers Squibb to present new data on BARACLUDE and other compounds at the AASLD 2009

New technique for blood diagnosis developed

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Hepatitis B News and Research

Latest Hepatitis B News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in